Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Non-Current Deffered Revenue: 2009-2025

Historic Non-Current Deffered Revenue for Gyre Therapeutics (GYRE) over the last 8 years, with Sep 2025 value amounting to $866,000.

  • Gyre Therapeutics' Non-Current Deffered Revenue rose 368.11% to $866,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $866,000, marking a year-over-year increase of 368.11%. This contributed to the annual value of $928,000 for FY2024, which is 335.68% up from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Non-Current Deffered Revenue is $866,000, which was down 2.04% from $884,000 recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Non-Current Deffered Revenue high stood at $928,000 for Q4 2024, and its period low was $118,000 during Q4 2022.
  • Over the past 3 years, Gyre Therapeutics' median Non-Current Deffered Revenue value was $539,500 (recorded in 2023), while the average stood at $547,000.
  • Data for Gyre Therapeutics' Non-Current Deffered Revenue shows a peak YoY skyrocketed of 368.11% (in 2025) over the last 5 years.
  • Gyre Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $118,000 in 2022, then skyrocketed by 80.51% to $213,000 in 2023, then skyrocketed by 335.68% to $928,000 in 2024, then surged by 368.11% to $866,000 in 2025.
  • Its Non-Current Deffered Revenue was $866,000 in Q3 2025, compared to $884,000 in Q2 2025 and $905,000 in Q1 2025.